Icon Legend

This session is not in your schedule.

This session is in your schedule. Click again to remove it.

Session: Diet and Cancer: Focus on Breast Cancer Prevention and Survivorship (Oral 25)

(OR25-04-23) Association of Mediterranean Diet With Survival After Breast Cancer Diagnosis Among Women in Nine European Countries

Tuesday, July 25, 2023

10:24 AM – 10:36 AM ET

Location: Constitution B

Presenting Author(s)

Carlota Castro-Espin, MSc, PhD student

PhD student
Catalan Institute of Oncology (ICO), Bellvitge Biomedical Research Institute (IDIBELL)
Sant Feliu de Llobregat, Catalonia, Spain

Disclosure(s): No relevant financial relationship(s) with ineligible companies to disclose.

Co-Author(s)

Carlota Castro Espin, MSc (she/her/hers)

PhD Student
Catalan Institute of Oncology (ICO), Bellvitge Institute for Biomedical Research (IDIBELL)
Sant Feliu de Llobregat, Catalonia, Spain
CB

Catalina Bonet, MSc

Catalan Institute of Oncology (ICO), Bellvitge Biomedical Research Institute (IDIBELL)
Hospitalet de Llobregat, Catalonia, Spain
CM

Crous-Bou Marta, PhD (she/her/hers)

Principal Investigator
Catalan Institute of Oncology (ICO)-Bellvitge Biomedical Research Center (IDIBELL)
Barcelona, Catalonia, Spain
Elio Riboli, Professor

Professor, Chair in Cancer Epidemiology and Prevention
School of Public Health, Faculty of Medicine, Imperial College London
London, England, United Kingdom
LD

Laure Dossus, PhD

International Agency for Cancer Research (IARC)
Carlota Castro-Espin, MSc, PhD student

PhD student
Catalan Institute of Oncology (ICO), Bellvitge Biomedical Research Institute (IDIBELL)
Sant Feliu de Llobregat, Catalonia, Spain
AA

Antonio Agudo, MD, PhD

Head, Unit of Nutrition and Cancer
Catalan Institute of Oncology (ICO)-Bellvitge Biomedical Research Center (IDIBELL)
Hospitalet de Llobregat, Catalonia, Spain

Disclosure(s):

Carlota Castro-Espin, MSc, PhD student: No relevant financial relationship(s) with ineligible companies to disclose.

Carlota Castro Espin, MSc: No relevant financial relationship(s) with ineligible companies to disclose.

Objectives: To investigate whether adherence to Mediterranean diet (MD) before a breast cancer (BC) diagnosis is associated with overall and BC-specific mortality.

Methods: Our population included 13270 incident BC cases from the European Prospective Investigation into Cancer and Nutrition (EPIC) study. Adherence to MD was estimated by means of the adapted relative Mediterranean diet (arMED), a 16-point score including 8 key components of MD that excludes alcohol. Multivariable Cox regression models were used to investigate the association between arMED and all-cause and BC-specific mortality by 3 categories of adherence to the score (low, medium, high) and by 3-unit increase in the score.

Results: After a mean follow-up of 8.6 years since diagnosis, 2340 women died, 1475 of them from BC. Compared to medium adherence, low arMED, representing low adherence to MD, was associated with a 13% higher risk of all-cause mortality (HR 1.13, 95%CI 1.01-1.26) and high arMED showed no statistically significant association with all-cause mortality (HR 0.94, 95%CI 0.84-1.05). A 3-unit increase in arMED score was associated with 8% lower risk of all-cause mortality (HR 0.92, 95%CI 0.87-0.97) and this result was sustained when restricted to postmenopausal women. The arMED score was not associated to BC-specific mortality.

Conclusions: Following a Mediterranean diet before a breast cancer diagnosis may be a beneficial lifestyle choice to improve the prognosis of breast cancer survivors, particularly among postmenopausal women.

Funding Sources: C Castro-Espin is funded by Instituto de Salud Carlos III - Grant FI19/00197 (Co-funded by European Social Fund. ESF investing in your future)

This work has been carried out within the framework of a project supported by the following grants: Instituto de Salud Carlos III through the project PI18/00190 (Co-funded by European Regional Development Fund. ERDF, a way to build Europe). PRYES211366AGUD funded by the Scientific Foundation of the AECC.

The coordination of EPIC is financially supported by International Agency for Research on Cancer (IARC) and by the Department of Epidemiology and Biostatistics, School of Public Health, Imperial College London, which receives infrastructure support from the NIHR Imperial Biomedical Research Centre (BRC).

We thank CERCA Programme / Generalitat de Catalunya for institutional support.